Aerius

RSS

desloratadine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Aerius. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Aerius.

This EPAR was last updated on 09/06/2022

Authorisation details

Product details
Name
Aerius
Agency product number
EMEA/H/C/000313
Active substance
desloratadine
International non-proprietary name (INN) or common name
desloratadine
Therapeutic area (MeSH)
  • Rhinitis, Allergic, Perennial
  • Urticaria
  • Rhinitis, Allergic, Seasonal
Anatomical therapeutic chemical (ATC) code
R06AX27
Publication details
Marketing-authorisation holder
N.V. Organon
Revision
47
Date of issue of marketing authorisation valid throughout the European Union
15/01/2001
Contact address

Kloosterstraat 6
5349 AB, Oss
Netherlands

Product information

30/05/2022 Aerius - EMEA/H/C/000313 - PSUSA/00000962/202107

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antihistamines for systemic use

Therapeutic indication

Aerius is indicated for the relief of symptoms associated with:

  • allergic rhinitis;
  • urticaria.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating
Average
4 ratings
1 rating
1 rating